Cell Therapy Human Raw Materials Market Size Is Expected To Reach USD 11.44 Billion By 2030

 San Francisco, 1 April 2024: The Report Cnaverell Therapy Human Raw Materials Market Size, Share & Trends Analysis Report, By Product (Cell Culture Media, Cell Culture Sera, Cell Culture Supplements), By End Use, By Region, And Segment Forecasts, 2024 - 2030

The global cell therapy human raw materials market size is expected to reach USD 11.44 billion by 2030 and is projected to expand at a CAGR of 22.32% from 2024 to 2030 according to a new report by Grand View Research, Inc. This is attributed to increasing investment in cell therapy research & development, growing number of clinical trials and rising adoption of regenerative & personalized medicines.

The field of cell therapy R&D has seen substantial growth in investments in recent years, fueling the development of next-generation treatments like CAR T-cell therapies. This surge in activity has advanced the understanding of cell biology, immunology, & gene editing, leading to the identification of novel therapeutic targets and the optimization of cell manufacturing processes. The improved understanding of the tumor microenvironment and immune system evasion mechanisms has enabled researchers to design CAR-T cells that effectively target and eliminate cancer cells. These advancements are being driven by increased funding in cancer immunotherapy research and are expected to propel the cell therapy raw materials market. For instance, in August 2023, Cellares, a startup specializing in cell therapy production, secured an additional USD 255 million in funding as investors continued to invest heavily in the company. Bristol Myers Squibb is among the supporters of Cellares, which asserts that its manufacturing capabilities can outperform traditional Contract Development and Manufacturing Organization (CDMO) facilities.

Furthermore, the expanding landscape of clinical trials in the field of cell therapy has become a driving force influencing the cell therapy human raw materials market. As the number of clinical trials investigating the efficacy and safety of cell-based therapies continues to rise, the demand for specific raw materials essential to these trials is experiencing a considerable upswing.

However, ethical concerns in stem cell research restrain the cell therapy human raw materials market, shaping the landscape with unique challenges. One prominent ethical dilemma revolves around the use of human-derived materials, particularly stem cells, which raises issues regarding the source, consent, and potential exploitation. Obtaining these materials may involve ethical considerations related to embryonic stem cells, as their extraction typically involves the destruction of embryos, sparking debates on the moral status of the early human life involved.

Access Research Report of Cell Therapy Human Raw Materials Market @ https://www.grandviewresearch.com/industry-analysis/cell-therapy-human-raw-materials-market-report

Cell Therapy Human Raw Materials Market Report Highlights

• The cell culture supplements segment dominated the product segment with a revenue share of 27.84% in 2023, owing to the rising demand for animal-free cell-based therapies
• The cell culture media segment is expected to grow at the fastest CAGR over the forecast period due to the advancements in cell culture media technology which focuses on development of specialized formulations
• Based on end use, the biopharmaceutical & pharmaceutical companies segment dominated the market in 2023. On the other hand, the CROs & CMOs segment is expected to witness the fastest growth over the forecast period
• North America region dominated the market owing to factors such as the presence of key market players like Thermo Fisher Scientific, Inc, Actylis, ACROBiosystems and the growth in pharmaceutical & biotechnology research sectors in this region
• Asia Pacific is expected to register the fastest growth over the forecast period due to several companies expanding their presence in regions like Japan

Cell Therapy Human Raw Materials Market Report Scope

Report Attribute	Details
Market size value in 2024	USD 3.42 billion
Revenue forecast in 2030	USD 11.44 billion
Growth rate	CAGR of 22.32% from 2024 to 2030
Base year for estimation	2023
Historical data	2018 - 2022
Forecast period	2024 - 2030

List of Key Players in the Cell Therapy Human Raw Materials Market

• Thermo Fisher Scientific, Inc
• Merck KGaA
• Actylis
• ACROBiosystems
• STEMCELL Technologies
• Grifols, S.A.
• Charles River Laboratories
• RoosterBio, Inc.
• PromoCell GMBH
• Danaher
• BioIVT
• GeminiBio
• Akron Biotech
• AllCells
• CGT Global

Access Press Release of Cell Therapy Human Raw Materials Market @ https://www.grandviewresearch.com/press-release/global-cell-therapy-human-raw-materials-market